![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Saturday, December 02, 2017 9:02:22 PM
I see you asked this question twice and got no response. However, you provided some rather sound analysis yourself. Which is good because a question such as yours is one each must answer for themselves. However, I found your post helpful and enlightening.
If FDA agrees that A2-73 could be approved by reaching intermediate endpoints for symptomatic relief such as Relief from Insomnia, Improvement in Mood, Irritability and Agitation and other symptoms short of the harder to reach ultimate goals of slowing or reversing decline in cognition and memory then knowing what we know and if these findings play out in the larger trial then one would think the chances for approval of A2-73 are excellent. Symptomatic relief alone would make A2-73 a blockbuster drug.. The bar for approval is set low.
Of course, the trials and research into the penultimate goals of cognition and memory would continue. A2-73 might be approvable on the intermediate symptomatic endpoints it all depends on what the FDA agrees on as the various endpoints.
Market participants might be waiting to see what these endpoints will be, this is why the trial starts might be a catalyst, not the starting of the trials per se rather the disclosure of the Trial Designs and FDA Approved Endpoints for A2-73 approval.
Other posters started this thread yesterday where I replied thus:
Potentially HUGE near-term catalyst for A2-73 development as well as stock price was recently illuminated by Mrplmr and Bourbon in this thread of posts:
Quote:
Bourbon_on_my_cornflakes Thursday, 11/30/17 01:48:12 PM
Re: mrplmer post# 132419
Post #
132420
of 132518 Go
"Authority under FDASIA to grant accelerated approval based on intermediate clinical endpoints"
hmm, could insomnia prevention be an intermediate clinical endpoint for alz? you would know that in 3 months!
Take a moment to ponder the gravity of this particular point. Some have opined that the start of the trials will not be a stock moving event. Of course, these are expected. If they start before end of the year there may be some relief rally to the extent that delay was baked into the recent slide. However that is not the point!
The point is the unveiling of the Trial Designs together with the FDA agreed endpoints particularly the Alzheimer's P2/3 design and plan.
Now if the FDA agrees that there are intermediate endpoints that could be reached that would provide immediate and safe relief to Alzheimer's victims, such as relief from insomnia, agitation, mood and other symptomatic benefits short of the penultimate goal of preventing (or slowing) decline of cognition and other traditional and hard to reach endpoints what would the New FDA be mandated by the 21st Century Cures Act to do?
How would this speed the development of A2-73?
How might the Market react to this highly achievable intermediate approval scenario?
I know many of you have carried a heavy risk load for a long time. Hang in there the reward may come in the next three weeks.
Good Luck to all Honest Longs.
On another note,
I think you are right on the TD Sequences, it looks like a marginal 8 Friday on the set-up on daily chart so we could see the 9 on Monday. AVXL seems to reverse on the 9 set-ups and not wait for the 13 countdowns. It flipped on a 9 setup 10/24/17 to reverse into the slide we are in now. So maybe we will get a reversal just in anticipation of news but it would seem any good news will start the reversal.
Thank you for all your great posts Sokol.
Good Luck to all Longs!
Go Anavex>>>>>>>>
Recent AVXL News
- Anavex Life Sciences Announces Expansion of Leadership Team • GlobeNewswire Inc. • 05/22/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 10:01:00 AM
- Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ • GlobeNewswire Inc. • 05/14/2024 11:30:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) Urged to Join Class Action - Contact The Gross Law Firm to Learn More • PR Newswire (US) • 05/10/2024 09:45:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:35:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 12:00:30 PM
- Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/09/2024 11:30:00 AM
- The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corporation(AVXL) Shareholders • PR Newswire (US) • 05/07/2024 09:45:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/06/2024 10:03:33 AM
- Anavex Life Sciences Corporation Sued for Securities Law Violations - Contact The Gross Law Firm Before May 13, 2024 to Discuss Your Rights - AVXL • PR Newswire (US) • 05/03/2024 09:45:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024 • GlobeNewswire Inc. • 05/02/2024 11:30:00 AM
- May 13, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against AVXL • PR Newswire (US) • 04/26/2024 09:45:00 AM
- Contact The Gross Law Firm by May 13, 2024 Deadline to Join Class Action Against Anavex Life Sciences Corporation(AVXL) • PR Newswire (US) • 04/19/2024 09:45:00 AM
- The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 13, 2024 in Anavex Life Sciences Lawsuit - AVXL • PR Newswire (US) • 04/16/2024 09:45:00 AM
- Class Action Filed Against Anavex Life Sciences Corporation (AVXL) - May 13, 2024 Deadline to Join - Contact The Gross Law Firm • PR Newswire (US) • 04/12/2024 09:45:00 AM
- Anavex Life Sciences to Present at the Noble Capital Markets Virtual Healthcare Equity Conference • GlobeNewswire Inc. • 04/11/2024 11:30:00 AM
- Class Action Filed Against Anavex Life Sciences Corporation (AVXL) - May 13, 2024 Deadline to Join - Contact The Gross Law Firm • PR Newswire (US) • 04/09/2024 09:45:00 AM
- Anavex Life Sciences Corporation Class Action: The Gross Law Firm Reminds Anavex Life Sciences Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 13, 2024 - AVXL • PR Newswire (US) • 04/05/2024 09:45:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) should contact The Gross Law Firm about pending Class Action - AVXL • PR Newswire (US) • 04/02/2024 09:45:00 AM
- Lost Money on Anavex Life Sciences Corporation(AVXL)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm • PR Newswire (US) • 03/29/2024 09:45:00 AM
- Investors who lost money on Anavex Life Sciences Corporation(AVXL) should contact The Gross Law Firm about pending Class Action - AVXL • PR Newswire (US) • 03/26/2024 09:45:00 AM
- Anavex Life Sciences to Present at the 23rd Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 03/25/2024 11:30:00 AM
- The Gross Law Firm Notifies Anavex Life Sciences Corporation Investors of a Class Action Lawsuit and Upcoming Deadline • PR Newswire (US) • 03/22/2024 09:45:00 AM
- Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia • GlobeNewswire Inc. • 03/18/2024 11:30:00 AM
FEATURED Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • Jun 14, 2024 2:07 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Snakes & Lattes Opens Pop-Up Location at The Wellington Market in Toronto: A New Destination for Fun and Games - Thanks 'The Well', PepsiCo, Indie Pale House & All Sponsors & Partners for Their Commitment & Assistance Throughout The Process • FUNN • Jun 13, 2024 8:18 AM
HealthLynked Introduces Innovative Online Medical Record Request Form Using DocuSign • HLYK • Jun 12, 2024 8:00 AM
Ubiquitech Software Corp (OTC:UBQU) Posts $624,585 Quarterly Revenue - Largest Quarter Since 2018 • UBQU • Jun 11, 2024 10:13 AM
Element79 Gold Corp Files for OTCQB Uplisting, Provides Financial Update • ELEM • Jun 11, 2024 9:25 AM